Filing Details
- Accession Number:
- 0001415889-25-011570
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-04-30 16:09:38
- Reporting Period:
- 2025-03-27
- Filing Date:
- 2025-04-30
- Accepted Time:
- 2025-04-30 16:09:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1785530 | Werewolf Therapeutics Inc. | HOWL | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1134657 | Luke Evnin | C/O Mpm Bioimpact Llc 399 Boylston Street, Suite 1100 Boston MA 02116 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-27 | 28,113 | $0.09 | 4,312,285 | No | 4 | X | Indirect | See Footnote |
| Common Stock | Disposition | 2025-03-27 | 2,425 | $1.05 | 4,309,860 | No | 4 | S | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | X | Indirect | See Footnote |
| No | 4 | S | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Warrant (Right to Buy) | Disposition | 2025-03-27 | 4,015 | $0.00 | 4,015 | $0.09 |
| Common Stock | Warrant (Right to Buy) | Disposition | 2025-03-27 | 24,098 | $0.00 | 24,098 | $0.09 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-04-09 | No | 4 | X | Indirect | |
| 0 | 2025-08-13 | No | 4 | X | Indirect |
Footnotes
- On March 27, 2025, the Reporting Person exercised warrants to purchase an aggregate of 28,113 shares of the Company's Common Stock for $0.09 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Company's withholding of 2,425 of the warrant shares to pay the exercise price and issuing the remaining 25,688 shares.
- The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 640,121 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014 and 639,659 by MPM OIF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein
- Immediately exercisable.
- The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B) and 125 by AM BV 2014.
- The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014 and 5,355 by MPM OIF.
Billionaire Hedge Funds
